Final Take: Know Your Options, Protect Your Wallet The almost instant success and widespread adoption of semaglutide and other GLP-1s has taken insurance companies, regulators, and federal and state health care programs completely off guard
Semaglutide is a synthetic peptide modeled after GLP-1, a hormone that helps control blood sugar and appetite
Novo Nordisk presented new data at the 2026 Scientific Sessions of the American Diabetes Association highlighting the impact of semaglutide across various weight-related conditions, including obstructive sleep apnea (OSA)
However, patients who lose significant weightwhether through medication, surgery, or lifestyle changesoften maintain a slightly lower metabolic rate than predicted for their new body weight
When significant weight is lost, particularly over a relatively short period, the reduction in mechanical load may lead to adaptive bone loss